Thymosin beta-4
- Generic Name
- Thymosin beta-4
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 77642-24-1
- Unique Ingredient Identifier
- 549LM7U24W
- Background
Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 40
- Registration Number
- NCT06607926
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China
Immuno-effect of Tα1 for Stage I NSCLC
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Yousheng Mao
- Target Recruit Count
- 40
- Registration Number
- NCT06598839
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Thymosin Alpha-1 for irAE Secondary to ICIs
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Jun Wang
- Target Recruit Count
- 40
- Registration Number
- NCT06178146
- Locations
- 🇨🇳
The first affiliated hospital of Shandong First Medical University, Jinan, Shandong, China
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 114
- Registration Number
- NCT06139419
- Locations
- 🇨🇳
Sun yat-sen university cancer center, Guangzhou, Guangdong, China
Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Nanjing Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT05487469
- Locations
- 🇨🇳
The first affiliated hospital of nanjing medical university, Nanjing, Jiangsu, China
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2500
- Registration Number
- NCT05086614
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Long-term Prognosis of Patients With Sepsis After Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 900
- Registration Number
- NCT04901104
Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04524169
- Locations
- 🇨🇳
Diansan Su, Shanghai, Shanghai, China
Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 2944
- Registration Number
- NCT04320238
- Locations
- 🇨🇳
Taihe Hospital, Shiyan, Hubei, China
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 69
- Registration Number
- NCT03659578
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.